Amanda Becker1, Dianna Gaballa1, Mitchell Roslin1,2,3, Eugenia Gianos1,3, Jamie Kane4,5,6,7,8. 1. Lenox Hill Hospital, New York, NY, USA. 2. Northern Westchester Hospital, Mount Kisco, NY, USA. 3. Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Uniondale, NY, USA. 4. Lenox Hill Hospital, New York, NY, USA. Jkane1@northwell.edu. 5. Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Uniondale, NY, USA. Jkane1@northwell.edu. 6. North Shore University Hospital, Manhasset, NY, USA. Jkane1@northwell.edu. 7. Syosset Hospital, Syosset, NY, USA. Jkane1@northwell.edu. 8. Northwell Health, New York, NY, USA. Jkane1@northwell.edu.
Abstract
PURPOSE OF REVIEW: Cardiovascular disease (CVD) is highly associated with obesity and cardiometabolic dysfunction. This review will focus on three novel therapies that have been identified for potential treatment of obesity and its associated CVD risk factors. RECENT FINDINGS: Intermittent fasting (IF) studies in animal models have shown improvements in cardiometabolic factors, including improved glucose metabolism, reduced inflammation, and reduced blood pressure. However, there is still a lack of prospective human trials to support results from animal-based studies and observational data. Studies of ketogenic diets in humans have produced mixed effects in CVD risk factors. It has been shown that the ketogenic diet (KD) increases low-density lipoprotein cholesterol (LDL-C) but decreases triglycerides. Additionally, implementation of KD in rodent studies have demonstrated increased insulin resistance and glucose intolerance. Bariatric surgery is a useful tool to help patients with obesity lose significant amounts of weight while alleviating CVD risk factors such as hypertension, LDL-C levels, triglyceride levels, and diabetes. The type of procedure influences degree of improvement in weight and CVD risk factors, yet complications remain possible. IF and bariatric surgery offer potential for weight loss and treatment of CVD risk factors. Negative cardiovascular effects of KD have been noted and should be considered before recommending this diet to patients, particularly those with established cardiovascular disease.
PURPOSE OF REVIEW: Cardiovascular disease (CVD) is highly associated with obesity and cardiometabolic dysfunction. This review will focus on three novel therapies that have been identified for potential treatment of obesity and its associated CVD risk factors. RECENT FINDINGS: Intermittent fasting (IF) studies in animal models have shown improvements in cardiometabolic factors, including improved glucose metabolism, reduced inflammation, and reduced blood pressure. However, there is still a lack of prospective human trials to support results from animal-based studies and observational data. Studies of ketogenic diets in humans have produced mixed effects in CVD risk factors. It has been shown that the ketogenic diet (KD) increases low-density lipoprotein cholesterol (LDL-C) but decreases triglycerides. Additionally, implementation of KD in rodent studies have demonstrated increased insulin resistance and glucose intolerance. Bariatric surgery is a useful tool to help patients with obesity lose significant amounts of weight while alleviating CVD risk factors such as hypertension, LDL-C levels, triglyceride levels, and diabetes. The type of procedure influences degree of improvement in weight and CVD risk factors, yet complications remain possible. IF and bariatric surgery offer potential for weight loss and treatment of CVD risk factors. Negative cardiovascular effects of KD have been noted and should be considered before recommending this diet to patients, particularly those with established cardiovascular disease.
Authors: Linda Van Horn; Jo Ann S Carson; Lawrence J Appel; Lora E Burke; Christina Economos; Wahida Karmally; Kristie Lancaster; Alice H Lichtenstein; Rachel K Johnson; Randal J Thomas; Miriam Vos; Judith Wylie-Rosett; Penny Kris-Etherton Journal: Circulation Date: 2016-10-27 Impact factor: 29.690
Authors: John F Trepanowski; Cynthia M Kroeger; Adrienne Barnosky; Monica C Klempel; Surabhi Bhutani; Kristin K Hoddy; Kelsey Gabel; Sally Freels; Joseph Rigdon; Jennifer Rood; Eric Ravussin; Krista A Varady Journal: JAMA Intern Med Date: 2017-07-01 Impact factor: 21.873
Authors: Elizabeth F Sutton; Robbie Beyl; Kate S Early; William T Cefalu; Eric Ravussin; Courtney M Peterson Journal: Cell Metab Date: 2018-05-10 Impact factor: 27.287
Authors: Stephen D Anton; Keelin Moehl; William T Donahoo; Krisztina Marosi; Stephanie A Lee; Arch G Mainous; Christiaan Leeuwenburgh; Mark P Mattson Journal: Obesity (Silver Spring) Date: 2017-10-31 Impact factor: 5.002
Authors: Dylan A Lowe; Nancy Wu; Linnea Rohdin-Bibby; A Holliston Moore; Nisa Kelly; Yong En Liu; Errol Philip; Eric Vittinghoff; Steven B Heymsfield; Jeffrey E Olgin; John A Shepherd; Ethan J Weiss Journal: JAMA Intern Med Date: 2020-11-01 Impact factor: 21.873